Search Results

Business

Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.

June 22, 2023

·

5 min read

Business

Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.

June 22, 2023

·

6 min read

Policy

Lawsuits Galore: J&J, BMS, GSK, Mylan and Others

Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit over a generic multiple sclerosis drug developed by India-based Natco, Gland Pharma and Mylan.

May 25, 2022

·

2 min read

·

Alex Keown

John Tlumacki/The Boston Globe via Getty Images

Drug Development

Appeals Court Upholds Decision for Mylan Generic of Biogen MS Drug

The U.S. Court of Appeals for the Federal Circuit denied Biogen a second look into the patent dispute filed against Mylan for Biogen’s Multiple Sclerosis (MS) drug, Tecfidera.

March 17, 2022

·

2 min read

·

Jazmine Colatriano, M.S.

Genetown

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.

December 19, 2023

·

4 min read

Policy

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan N.V. and Pfizer Inc. announced that the U.S. Federal Trade Commission accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.

October 30, 2020

·

13 min read

Business

Mylan Board Appoints Robert J. Coury As Executive Chairman of Mylan N.V.

The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced the appointment of Robert J. Coury , previously chairman of the Mylan Board, to the position of executive chairman of Mylan. Given the unprecedented current operating environment due to the COVID-19 pandemic, the extensive ongoing activity

April 15, 2020

·

12 min read

Pharm Country

Mylan Shareholders Overwhelmingly Approve Proposed Combination with Upjohn

Mylan N.V. (Nasdaq: MYL) today announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company’s extraordinary general meeting of shareholders.

June 30, 2020

·

12 min read